DNAEID
17/02/2025
"
MESOBLAST BREAKTHROUGH: RYONCIL® NOW COVERS 100M+ U.S. LIVES!
Agame-changing leapfor patients—and investors.
Mesoblast justsmashed barriers, securing unprecedented insurance coverage for its lifesaving GVHD therapy,Ryoncil®.
Over100 million Americanscan now access this revolutionary treatment, catapulting commercial potential into the stratosphere.
Payers are voting with their policies—and the verdict is clear: Ryoncil is WORTH IT.
This isn’t just expansion—it’s a tidal wave of validation, setting the stage for explosive revenue growth.
The clock is ticking. The market won’t stay asleep on this.
Mesoblast isn’t just playing the game—it’s rewriting the rules. "
I concur
Molly
Ryoncil
"Saving kids lives"
(20min delay)